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In the immune system, many tolerance checkpoints exist to prevent self-antigens from stimu-
lating the relentless growth of self-reactive B and T lymphocytes. The genes and molecular 
pathways underpinning these checkpoints overlap with those involved in tumor suppression. 
As with an inherited predisposition to cancer, inherited defects in self-tolerance genes typi-
cally precipitate autoimmune disease stochastically after a latent phase. Multiple mutations, 
inherited and somatic, may be needed before a self-reactive clone bypasses sequential toler-
ance checkpoints resulting in the emergence of autoimmune disease.Introduction
Why does autoimmunity develop in about 5% of people? 
Autoimmune diseases arise when the immune system 
turns its antimicrobial defenses upon normal compo-
nents of the body such as insulin-producing pancreatic 
cells in Type 1 diabetes or chromatin in systemic lupus 
erythematosus. Immunologists have identified a number 
of specific genes and cellular mechanisms involved in 
immunological self-tolerance that, when disrupted by 
inherited mutations, cause autoimmune disease. Despite 
complete failure of individual tolerance mechanisms, 
these autoimmune diseases have a delayed stochastic 
penetrance that resembles the onset of cancer resulting 
from inherited mutations in tumor suppressor proteins 
such as p53. Such tumors have delayed stochastic pen-
etrance because other regulatory layers prevent aber-
rant cells from accumulating and are only bypassed after 
multiple somatic mutations accumulate in a single clone. 
Multiple control systems also prevent accumulation of 
autoimmune lymphocytes, and these control systems 
depend on genes known to suppress lymphoid cancers 
such as B cell lymphoma and myeloma. This Review 
analyzes the parallels and overlaps in the evolution of 
rogue lymphocyte clones in autoimmune diseases and 
lymphoid cancer, drawing together concepts from the 
latter that inform our understanding of autoimmunity.
Relentless Stimulation of Lymphocyte Growth
Physiological mechanisms of V(D)J recombination, 
gene conversion, and somatic mutation equip the T 
and B lymphocytes of our immune system with different 
receptors for detecting antigen. T lymphocytes express 
T cell receptors (TCRs), and B cells express B lympho-
cyte receptors (BCRs), which are membrane-spanning 
immunoglobulin isoforms. When engaged by antigen, 
these receptors can switch on powerful cell growth and 
survival pathways. For example, the transcription fac-tor nuclear factor kappa B (NF-κB) activates a range 
of growth and survival factors; phosphatidylinositol-3-
kinase (PI3K) activates the protein kinase AKT; Ras acti-
vates ERK; MYC activates many cellular growth genes; 
and the BCL-2, BCL-XL, and A1(Bfl1) proteins suppress 
apoptosis. Activation of these pathways by antigen trig-
gers clonal lymphocyte proliferation, mobilizing immu-
nity against infection (Figure 1).
Lymphoid cancers arise from uncontrolled activity of 
these cell growth and survival pathways. Constitutively 
active aberrant antigen receptors promote lymphoid 
cancer: for example, truncated BCRs (Corcos et al., 
2001) in lymphoma and myeloma, or uncontrolled activ-
ity of the preTCR in T cell acute lymphoblastic leukemia 
(Winandy et al., 1999). Viral gene products act down-
stream to mimic constitutively active antigen receptors, 
illustrated by leukemogenic retroviruses expressing 
mutated versions of MYC and NF-κB c-REL (Grumont 
et al., 2002) and by the Epstein-Barr virus transform-
ing protein LMP2A (Casola et al., 2004). Chromosomal 
translocations that constitutively activate MYC, BCL-2, 
or upstream activators of NF-κB (BCL-10, MALT-1) are 
found in many human lymphomas.
Relentless stimulation of antigen receptors and lym-
phocyte growth can also arise upstream of antigen 
receptors. Chronic infection provides a constantly 
replenished supply of antigen to stimulate lymphocytes; 
for example, infections with the bacterium Helicobacter 
pylori, hepatitis C virus, or human immunodeficiency virus 
predispose individuals to lymphoid cancer (Suarez et al., 
2006). Dietary antigens also stimulate antigen receptors 
relentlessly, and chronic T lymphocyte responses to 
wheat gluten can progress from intestinal inflammation 
to intestinal lymphoma (Cellier et al., 2000).
The diverse array of self-antigens poses the greatest 
potential source for relentless lymphocyte stimulation. 
More than half of all antigen receptors randomly gen-Cell 130, July 13, 2007 ©2007 Elsevier Inc. 25
Figure 1. Keeping Lymphocyte Growth under Control 
Multiple control mechanisms limit or override the potential for antigen receptors to stimulate relentless growth of lymphocytes. Binding of antigen to an-
tigen receptors can activate potent growth and survival signaling pathways (black arrows). In lymphocytes recognizing microbial antigens, these signals 
drive clonal expansion of antimicrobial lymphocytes. Once the microbe is eliminated this removes the source of antigen and induction of clonal growth. 
Self-antigens cannot be cleared in this way, posing the potential for chronic receptor activation and endless growth induction in self-reactive clones. 
Mutations that cripple mechanisms for countering this potential lead to outgrowth of autoimmune disease clones and to lymphoid malignancy.erated by V(D)J recombination recognize self-antigens 
(Ignatowicz et al., 1996; Wardemann et al., 2003; Zerrahn 
et al., 1997). Given that millions of new lymphocytes are 
produced daily, there is a massive flow of lymphocytes 
into the system with the potential for endless growth 
stimulation by self-antigen.
Keeping Autoimmune Lymphocyte Growth in Check
Growth of autoimmune lymphocytes induced by self-
antigens is blocked by mechanisms that either override 
or limit antigen receptor signaling to NF-κB, PI3K/AKT, 
MYC, and BCL-2/BCL-XL/A1 (Figure 1). These mecha-
nisms act as distinct checkpoints placed along the lym-
phocyte differentiation and activation sequence (Figure 
2). The different checkpoints are reviewed systematically 
elsewhere (Goodnow et al., 2005), and we will focus here 
on several better understood checkpoints that illustrate 
key concepts.
Negative selection of thymocytes illustrates an effi-
cient override mechanism. When V(D)J recombination in 
immature thymic T cells yields a TCR binding strongly to 
self-antigen, the TCR signals transcription and synthe-
sis of BIM, a proapoptotic BH3-only protein that inhibits 
the antiapoptotic proteins BCL-2 and BCL-XL (Liston et 
al., 2004; Strasser, 2005). BIM-induced apoptosis elimi-
nates strongly self-reactive thymocytes, and inherited 
BIM deficiency in mice cripples this process and pre-
disposes them to autoimmunity and to lymphoid can-
cer (Egle et al., 2004b; Strasser, 2005). The FAS/CD95 
receptor provides a complementary mechanism to over-
ride growth stimulation by self-antigens in peripheral T 
and B cells (Krammer, 1999; Nagata and Golstein, 1995). 
FAS ligand is induced by antigen on T cells and triggers 
apoptosis of self-reactive T and B cells through FAS sig-
naling to caspases 8 and 10. Like BIM, FAS also exem-26 Cell 130, July 13, 2007 ©2007 Elsevier Inc.plifies the molecular overlap between self-tolerance and 
tumor suppression because both autoimmune disease 
and lymphoma arise in humans and mice with inherited 
FAS mutations (Nagata and Golstein, 1995; Rieux-Lau-
cat et al., 1995; Straus et al., 2001). Moreover, somatic 
FAS mutations have been documented in autoimmune 
disease (Holzelova et al., 2004) and in lymphoma (Gron-
baek et al., 1998).
An overlapping set of growth-limiting mechanisms 
also counters the potential for self-antigen to stimulate 
relentless activation of NF-κB, PI3K/AKT, c-MYC, and 
BCL-2/BCL-XL/A1 pathways. Growth of T cells requires 
costimulation by a second signal (Lafferty et al., 1983) 
delivered through the CD28 receptor (Greenwald et al., 
2005; Kane et al., 2002). In naive T cells, TCR engage-
ment alone activates PI3K and NF-κB pathways ineffi-
ciently, so that high amounts of antigen are needed to 
induce production of the autocrine T cell growth factor 
interleukin (IL)-2. Insufficient induction renders the cell 
refractory to TCR stimulated growth—a phenomenon 
termed anergy. When TCR engagement alone is suffi-
cient to initiate proliferation, it is overridden by apopto-
sis because of insufficient induction of the NF-κB target, 
BCL-XL (Boise et al., 1995). These outcomes predomi-
nate in peripheral T cells that recognize self-antigens 
as they are usually stimulated by their TCR alone. When 
antigen-presenting cells capture and present micro-
bial antigens, however, they transiently express B7.1 
and B7.2, which are ligands that activate CD28 and 
dramatically enhance TCR activation of PI3K/AKT and 
NF-κB (Kane et al., 2002; Narayan et al., 2006). CD28 
costimulation thus selectively relieves a critical growth 
limitation in T cells that recognize microbial antigens. 
T cell dependence on CD28, and susceptibility to FAS-
induced apoptosis, is abolished when the PI3K pathway 
Figure 2. Checkpoints Exist at Multiple Stages in the Evolution of the Immune Response 
Tolerance mechanisms in central lymphoid organs: (1) TCR editing by V(D)J recombination; (2) thymic negative selection; (3) B and T cell anergy 
and inhibitory signaling; (4) FoxP3+ T regulatory cell differentiation; (5) immature B cell maturation arrest; (6) BCR editing by V(D)J recombination; 
and (7) immature B cell deletion.
Tolerance mechanisms in peripheral lymphoid organs: (3) B and T cell anergy and inhibitory signaling; (8) TCR or BCR induction of BIM; (9) T cell 
competition for IL-2, IL-7, IL-15, and peptide/MHC; (10) B cell competition for the survival cytokine BAFF; (11) T cell growth-dependence on CD28 
ligands and other costimulatory molecules; (12) elimination of antigen-bearing dendritic cells by activated T cells producing perforin or FasL; (13) 
suppression of T and B cells by Treg cells and TGF-β; (14) T cell death by FasL; (15) Regulation of T follicular helper cell differentiation and function; 
(16) B cell growth-dependence on extrafollicular T cell help (CD40L, IL-2, IL-4, etc.); (17) B cell growth-dependence on TLR ligands; (18) B cell death 
by FasL from T cells; (19) BCR inhibition of plasma cell differentiation; (20) B cell follicular exclusion; (21) BCR-induced death of germinal center B 
cells; and (22) germinal center B cell growth/survival dependence on follicular helper T cells (CD40L, IL21).
Tolerance mechanisms in target tissues: (23) control of effector T cell functions in tissues (inhibition by PD-1 ligands, dependence on MHC upregula-
tion by interferons, and inhibition by Treg cells and TGF-β); and (24) control of antibody extravasation and inflammation in tissues.is overactive due to an inherited deficiency of the PI3-
phosphatase, PTEN (Buckler et al., 2006; Di Cristofano 
et al., 1999; Jones et al., 2002; Marsh et al., 1999; Suzuki 
et al., 2001), representing another example of a control 
gene that, when mutated, results in a predisposition to 
both autoimmunity and cancer.
Chronic stimulation of the TCR induces feedback 
mechanisms that further limit the potential for relent-
less growth stimulation. One of these is CTLA4, a 
second receptor for B7.1 and B7.2 that opposes TCR-
CD28-induced proliferation by competing with CD28 
for its B7 ligands and by recruiting inhibitory tyrosine 
phosphatases that dampen TCR signaling (Greenwald 
et al., 2005). CTLA4-deficient mice develop a massive 
accumulation of activated polyclonal T cells, and CTLA-
4 abnormalities are associated with autoimmune sus-
ceptibility in humans (Ueda et al., 2003). Other inhibitory 
receptors induced by chronic TCR stimulation are CD5 
(Smith et al., 2001; Wong et al., 2001) and PD-1 (Green-
wald et al., 2005). Within the T cell, chronic TCR stimula-
tion induces the inhibitory ubiquitin ligase CBL-B (Heiss-
meyer et al., 2004) and, under particular conditions, the 
transcription factor FOXP3. FOXP3 induces CTLA4 and 
represses the tyrosine kinases ZAP-70 and ITK, IL-2, and the receptor for IL-7, a critical T cell survival factor 
provided by the lymphoid stroma (Wan and Flavell, 2007; 
Wu et al., 2006; Zheng et al., 2007). In self-reactive T 
cells expressing FOXP3, despite constant TCR stimula-
tion by self-antigens, cell growth and survival depends 
upon IL-2 provided by other T cells rather than autocrine 
IL-2 or IL-7 from the stroma (Gavin et al., 2007; Williams 
and Rudensky, 2007).
BCR engagement by antigen also has limited capacity 
to activate NF-κB, PI3K/AKT, MYC, and BCL-2/BCL-XL/
A1 growth pathways in B cells. Binding of chronic anti-
gen alone is usually insufficient to promote cell division, 
and instead induces inhibitory feedback mechanisms 
that make the cell anergic. Anergy in B cells involves 
selective uncoupling of the BCR from NF-κB signaling 
to MYC, BCL-XL, and A1 (Glynne et al., 2000), whereas 
BCR signaling that results in growth-override mecha-
nisms such as BIM-induced apoptosis remains intact 
(Strasser, 2005). The limits on BCR signaling for NF-κB 
activation and B cell growth are relieved when the BCR 
captures a microbial antigen. Simultaneous engagement 
of Toll-like receptors (TLRs) by microbial components—
such as the lipopolysaccharide cell walls of bacteria or 
double-stranded RNAs of virions—acts synergistically Cell 130, July 13, 2007 ©2007 Elsevier Inc. 27
with BCR stimulation to activate NF-κB, resulting in B cell 
proliferation (Beutler, 2004; Marshak-Rothstein, 2006). 
Microbial antigens are also tagged with the complement 
cleavage product C3d. When BCRs bind to C3d-tagged 
antigen, C3d simultaneously engages its CD21 receptor 
and, through preformed CD21/CD19 clusters, promotes 
BCR-induced phosphorylation of CD19, which is a major 
docking site for activation of PI3 kinase. This provides 
a second way to dramatically enhance proliferation of 
microbe-reactive, but not self–reactive, B cells (Fearon 
and Carroll, 2000).
Lymphocyte cooperation provides a major mecha-
nism for relieving growth-limiting checkpoints in cells 
responding to microbial antigens. Receptors for CD40 
ligand and IL-4 on B cells activate the NF-κB and PI3K/
AKT pathways, respectively, and act synergistically with 
BCR signaling to promote B cell growth and survival (Foy 
et al., 1996; Kovanen and Leonard, 2004). CD40L and IL-
4 are produced focally by CD4+ helper T lymphocytes 
that have themselves been success-
fully stimulated to grow. As many 
checkpoints override or limit self-
reactive T cell production of CD40L 
and IL-4, these are primarily made 
by T cells that recognize microbial 
antigens. Hence the potential for B 
cell growth in response to self-anti-
gen is limited by dependence on 
two cooperating cells (Bretscher and Cohn, 1970)—a B 
cell and a T cell—both of which must bypass multiple 
checkpoint mechanisms (Figures 2 and 3B). The prob-
ability of a two-cell failure is the square root of either 
one alone and hence constitutes a powerful checkpoint 
against autoantibody production.
Multiple Steps Cooperate in Autoimmunity
Autoimmune disease only develops after a considerable 
latent period in humans and experimental animals that 
inherit mutations completely disrupting individual toler-
ance checkpoints. For example, mutations in the tran-
scription factor AIRE cripple thymic negative selection 
of organ-specific T cells (Liston et al., 2003). A range of 
self-antigens that are made only in a particular organ, 
such as proinsulin expression in the pancreas, is also 
produced by specialized epithelial cells within the thy-
mus medulla. This specialized thymic display of the 
body’s repertoire of self-antigens depends in part upon 
Figure 3. Multistep Models for the 
Pathogenesis of Autoimmune Disease
Random somatic diversification of antigen 
receptor genes yields many clones bearing 
self-reactive receptors. 
(A) Normally, the survival and growth of these 
clones is opposed by multiple checkpoints. 
(B) When an inherited mutation (or a com-
bination of more subtle alleles) disrupts one 
checkpoint, other checkpoints still oppose 
survival and growth of most self-reactive 
clones. Rare clones eventually bypass these 
additional checkpoints on a stochastic ba-
sis. Cooperation between clones—for ex-
ample between B and T cells recognizing 
the same self-antigen—provides one bypass 
mechanism. When the frequency of self-re-
active cells increases because of an inher-
ited or somatic disruption of one checkpoint, 
the probability of forming cooperative pairs 
increases, explaining the stochastic onset of 
autoimmunity. 
(C) As opposed to an inherited defect, 
chance somatic mutations in a self-reactive 
clone may disrupt different growth-limit and 
override mechanisms so that self-antigen 
stimulates clonal growth, leading to sto-
chastic onset of autoimmunity. 
(D) Somatic mutations in separate self-reac-
tive clones may lead to cooperating groups 
of self-reactive clones that help each other 
to bypass unmutated checkpoints. Combi-
nations of (B), (C), and (D) are also likely—for 
example inheritance of a heterozygous mu-
tation that is rendered homozygous in rare 
clones by a somatic mutation.28 Cell 130, July 13, 2007 ©2007 Elsevier Inc.
AIRE and is extinguished when the AIRE gene is defec-
tive (Anderson et al., 2002). AIRE deficiency in humans 
nevertheless remains clinically latent for many years, 
with autoimmune polyendocrinopathy developing in an 
apparently stochastic, stepwise manner (Betterle et al., 
1998). Initially a single organ, often parathyroid or adre-
nal glands, is compromised in the first decade of life 
followed after several years by a second or third organ. 
A similar situation exists in Aire-deficient mice, where 
few organs and antigens become targets of autoimmu-
nity and only after a latent period, with both parameters 
changing depending on the mouse strain background 
and major histocompatibility complex (MHC) genotype 
(Jiang et al., 2005). Type 1 diabetes does not occur even 
in Aire-deficient B6 mice with a diabetes-prone MHC, 
despite failure of thymic negative selection to major 
islet-specific antigens. Severe exocrine pancreatitis 
nevertheless develops with a short latent period when 
the Aire-mutation is bred to the NOD strain harboring 
defects in many tolerance checkpoints, suggesting that 
autoimmune clones that escape thymic deletion must 
bypass several independent checkpoints before auto-
immunity develops.
Key factors affecting the latent period are most 
defined in lpr mice with homozygous inactivating muta-
tions in Fas (CD95, Tnfrsf6) because this is the longest 
studied autoimmune-inducing mutation (Cohen and 
Eisenberg, 1991; Nagata and Golstein, 1995). In inbred 
C57BL/6 or C3H mice, Fas mutation causes mild auto-
antibody secretion against DNA- and RNA-associated 
antigens and accumulation of B and T cells in lymph 
nodes starting after three months of age. Autoantibodies 
appear earlier and reach higher titers when the mutation 
is combined with an inherently autoimmune-prone strain 
background, MRL. The event(s) that trigger progression 
from latent to measurable autoimmunity in Fas-deficient 
mice do not involve an external trigger such as infection 
because autoimmunity occurs equally in germ-free ani-
mals (Maldonado et al., 1999).
Expanded B cell clones appear during progression to 
autoimmunity in Fas-deficient mice, bearing BCRs con-
taining V-elements and somatic V-region mutations that 
confer high affinity for DNA- and RNA-associated anti-
gens (Shlomchik et al., 1990). When V(D)J-recombina-
tion is distorted to produce particular BCRs by breeding 
BCR transgenes into Fas-deficient mice, transgenes that 
increase bone marrow formation of self-reactive B cells 
against DNA or RNA antigens shorten the latent period 
and increase autoantibody titers (Chen et al., 2006; San-
tulli-Marotto et al., 2001). By contrast, the latent period 
is prolonged by transgenes that increase self-reactive B 
cells against a nonchromatin self-antigen but decrease 
DNA-reactive B cells (Rathmell and Goodnow, 1994). 
Inherited mutations in TLR9 or TLR7 delay or suppress 
appearance of DNA- or RNA-reactive autoantibodies in 
Fas-deficient mice (Marshak-Rothstein, 2006), whereas 
the Yaa mutation that doubles TLR7 accelerates the 
onset and amount of autoantibody, particularly against RNA-associated antigens such as gp70, from endog-
enous retroviruses (Merino et al., 1989; Pisitkun et al., 
2006). Taking the above data together, the simplest 
explanation for the latent period in Fas-deficient mice 
is that a rate-limiting number of B cell clones are nor-
mally present in the peripheral lymphoid repertoire with 
a predisposing BCR specificity against DNA- or RNA-
associated self-antigens. Although Fas overrides T cell-
driven growth of many self-reactive B cells, these clones 
preferentially undergo clonal expansion in the absence 
of Fas because self-DNA and -RNA, when captured by 
the BCR, have an inherent capacity to trigger TLR7 and 
TLR9 as if it were of microbial origin, thus bypassing an 
important growth-limiting mechanism (Marshak-Roth-
stein, 2006).
The Fas example also reveals that bypass of TLR and 
Fas checkpoints in B cells is still insufficient for progres-
sion to autoimmunity because lymph node enlargement 
and autoantibodies require the Fas mutation in the T 
cell lineage as well (Cohen and Eisenberg, 1991). MHC-
Class II-reactive CD4 T cells in particular are required 
for development of anti-DNA autoantibodies in Fas-
deficient mice (Jevnikar et al., 1994; Koh et al., 1995), 
specifically their CD28 costimulatory receptor (Tada et 
al., 1999), their capacity to produce CD40 ligand (Ma et 
al., 1996), and their capacity to promote B cell growth 
and survival in germinal centers (Greenwald et al., 2005; 
Komori et al., 2006). Reciprocally, B cells are required to 
promote the accumulation of activated CD4 T cells and 
lymph node enlargement in mice lacking Fas (Chan et 
al., 1999). They may do this both by direct antigen pre-
sentation and indirectly by activating dendritic cells with 
secreted autoantibody complexes containing self-DNA 
or self-RNA (Goodnow, 2006). Multiple checkpoints 
must therefore be bypassed before autoimmunity arises, 
and genetic defects in one cell cooperate with defects 
in another cell to promote a feed-forward reaction that 
bypasses numerous growth-limit and override mecha-
nisms (Figures 3B and 3D).
Inherited defects in other checkpoints also cooper-
ate to shorten the latent phase of autoimmunity in Fas 
deficient mice. Lymph node enlargement is exaggerated 
when C57BL/6 Fas-deficient mice are also transgenic for 
BCL-2—a prosurvival opponent of BIM (Strasser et al., 
1995)—or if they lack Bim directly (A. Strasser, P. Bouil-
let, and P. Hughes, personal communication). Although 
BCL-2 overexpression or Bim deficiency has little effect 
on the Fas mechanism of death, it compromises at least 
four separate override mechanisms: thymic and periph-
eral deletion of self-reactive T cells and bone marrow 
and peripheral death of self-reactive B cells (Strasser, 
2005). When overexpression of BCL-2 is restricted to B 
cells in mice with intact Fas, this is insufficient to cause 
autoimmunity despite the fact that survival of self-reac-
tive B cells is dramatically increased at several tolerance 
checkpoints. Overexpression of BCL-2 selectively in T 
cells is equally insufficient to trigger autoimmune dis-
ease. However, when BCL-2 is expressed at sufficiently Cell 130, July 13, 2007 ©2007 Elsevier Inc. 29
high levels in B cells and CD4 cells, in C57BL/6 Vav:
BCL-2 transgenic strains, the combined defects lead to 
extensive B cell proliferation in germinal centers by 18 
weeks of age and lethal glomerulonephritis in 15%–25% 
of animals (Egle et al., 2004a). Of those that live greater 
than 40 weeks, more than 50% progress to follicular 
lymphoma. Both the germinal center proliferation and 
follicular lymphoma are suppressed when CD4 cells are 
selectively ablated from the animals. Hence it appears 
that cooperation between T cell and B cell defects is 
needed before B cells become sufficiently dysregulated 
that they cause autoimmunity or lymphoma (Figures 3B 
and 3D).
There are a small number of exceptional circum-
stances where autoimmunity develops without an 
apparent latent phase. Deficiency of CTLA4, TGF-β, or 
FOXP3 results in neonatal autoimmunity characterized 
by massive activation of T cells (Brunkow et al., 2001; 
Greenwald et al., 2005; Li et al., 2006; Marie et al., 2006). 
Similarly, human FOXP3 deficiency results in a neo-
natal-onset fatal autoimmune and allergic syndrome, 
immunodysregulation polyendocrinopathy and enter-
opathy X-linked (IPEX; Bennett et al., 2001). The loss 
of one gene and cell type, FOXP3+ CD4 cells, appar-
ently enables self-reactive T and B cell clones to bypass 
many other growth-limiting/override checkpoints (Kim et 
al., 2007). FOXP3 induces a gene program that inhibits 
growth of neighboring dendritic cells, T cells, and B cells 
at multiple checkpoints (Wan and Flavell, 2007; Wu et al., 
2006; Zheng et al., 2007). Unlike AIRE—which appears 
dedicated to regulating self-reactive cells—the suppres-
sive effects of FOXP3+ cells are also critical for damp-
ening immune responses to environmental antigens. 
Unbridled inflammation to gut bacteria and food in IPEX 
syndrome may activate dendritic cells and helper T cells 
that in turn allow self-reactive clones to bypass normal 
growth limits. CTLA4 and TGF-β also underpin multiple 
checkpoints, and both are necessary for the suppres-
sive effects of FOXP3+ CD4+ cells (Greenwald et al., 
2005; Li et al., 2006; Marie et al., 2006).
The evidence above for multiple cooperating events in 
the pathogenesis of autoimmune disease draws heavily 
from rare Mendelian disorders where complete defects 
are inherited. These results can be extrapolated to non-
Mendelian sporadic autoimmune disease by hypothesiz-
ing an accumulation of more subtle inherited defects in 
the same checkpoints (Liston et al., 2005). A substantial 
component of inherited risk of autoimmune disease is 
due to common variants of the MHC Class II molecules, 
which markedly change the efficiency of antigen presen-
tation for multiple T cell tolerance checkpoints (Vyse and 
Todd, 1996). Unlike mutations in FAS, AIRE, or FOXP3, 
however, autoimmunity due to susceptible MHC alleles 
has very low penetrance. Similarly, autoimmune suscep-
tibility in BXSB or NOD mice and KDP rats results from 
the additive effects of many different genetic loci, each 
of which has little or no capacity to cause autoimmune 
disease on its own (Fairhurst et al., 2006; Vyse and Todd, 30 Cell 130, July 13, 2007 ©2007 Elsevier Inc.1996). Several of these loci have recently been found to 
compromise the mechanisms described above: the NOD 
Idd5 locus alters the relative splicing of CTLA4 isoforms 
(Ueda et al., 2003); the BXSB Yaa gene duplicates the 
gene dose and responsiveness of TLR7 (Pisitkun et al., 
2006; Subramanian et al., 2006); and the KDP rat Iddm/
kdp1 locus is a nonsense mutation that inactivates CBL-
B (Yokoi et al., 2002).
Mutations in Autoimmunity and Lymphoma
The previous two sections summarize evidence that 
the potential for relentless growth of self-reactive lym-
phocytes is normally blocked by a series of checkpoint 
mechanisms that also prevent lymphoid neoplasia and 
that autoimmune outgrowths only develop when mul-
tiple checkpoints are eventually bypassed. The latent 
period and sporadic occurrence of autoimmune disease 
are often put down to an unknown environmental trig-
ger despite clear evidence to the contrary from MRL/lpr, 
NZB, and NOD mice raised in germ-free and antigen-
free conditions. Lymphoma also exhibits a latent period 
and sporadic occurrence, but in this case the explana-
tion is the need for accumulating somatic mutations 
in individual clones before they bypass normal growth 
control checkpoints. Here, I put forward the hypothesis 
that somatic mutations may represent one of the major 
stochastic elements in the pathogenesis of autoimmune 
disease (Figure 3).
The first reason for considering somatic mutations as 
a major factor in autoimmunity is because they occur 
often in lymphocytes. As discussed above, cooperation 
between inherited mutations in FAS and a specialized 
type of somatic mutation—V(D)J recombination and 
hypermutation of antibody genes—is already established 
in experimental animals. These specialized mechanisms 
of B cell somatic mutation, together with somatic muta-
tion during isotype switching, are error prone and known 
to activate oncogenes and inactivate tumor suppressor 
mechanisms in lymphoma, and they produce a high rate 
of somatic FAS mutations in normal human germinal 
centers (Muschen et al., 2000).
The basal rate of somatic mutation in hematopoietic 
cells itself creates a large burden. A revealing example 
comes from children presenting with all of the mani-
festations of inherited FAS mutations (Canale-Smith 
syndrome) but who have wild-type FAS genes in their 
germline (Holzelova et al., 2004). Autoimmunity in these 
individuals results from a somatic FAS mutation in a sin-
gle hematopoietic stem cell that contributes to a small 
fraction of blood cells. T cell progeny of this mutant 
clone, and presumably also autoantibody-secreting B 
cells, selectively expands to account for the severe dis-
ease and accumulation of characteristic CD4- CD8- T 
cells in the blood. Had the somatic mutation occurred 
in a mature T or B cell it is unlikely to have presented 
as Canale-Smith syndrome because the mouse models 
indicate the need for FAS mutations in both T and B lin-
eages to develop the corresponding disorder. However, 
a FAS mutation in a single B cell or T cell clone combined 
with other checkpoint defects might present as sporadic 
autoimmune disease.
Other examples of somatic mutation in hematopoi-
etic cells attest to their frequency. Paroxysmal noctur-
nal hemoglobinuria results from a PIGA mutation in a 
hematopoietic stem cell that disables the attachment of 
the complement inhibitory receptors CD48, CD55, and 
CD59 to the cell surface via phosphatidylinositol tails. 
Somatic mutations in this gene can be measured at a 
frequency of 22 blood cells in every million in normal 
individuals (Araten et al., 1999), with a new deleteri-
ous mutation arising once in every million cell divisions 
(Araten et al., 2005). Consequently, it is not surprising 
that somatic mutations in adenosine deaminase, IL-7 
receptor common gamma chain, or CD3 zeta, occur suf-
ficiently frequently within the first few years of life to give 
rise to multiple independent revertant T cells in people 
with inherited mutant alleles despite reversion requiring 
a specific mutation in a target as small as a single codon 
(Erickson, 2003; Rieux-Laucat et al., 2006). It is therefore 
inevitable that individual lymphocytes will acquire del-
eterious mutations in many of the tolerance mechanisms 
described above. Given the growth advantage conferred 
on self-reactive lymphocytes by such mutations, there 
seems a high potential for selection and acquisition of 
several mutations in a single clone (Figure 3C).
The second reason for considering somatic muta-
tions as a major stochastic element in the pathogen-
esis of autoimmunity comes from epidemiological evi-
dence for overlapping pathogenesis of autoimmunity 
and lymphoma. Large population studies (Bernatsky 
et al., 2005; Smedby et al., 2006; Zintzaras et al., 2005) 
show increased incidence of lymphoma in people with 
pre-existing systemic lupus, rheumatoid arthritis, and 
Sjogren’s syndrome and exclude the drugs used to con-
trol autoimmune diseases as a cause (Bernatsky et al., 
2006). The relationship might simply be explained by 
increased lymphocyte proliferation increasing somatic 
mutations. However a similarly elevated risk is not seen 
in other chronic immune responses, such as allergic 
disease (Soderberg et al., 2006) or inflammatory bowel 
disease (Smedby et al., 2006). Moreover, in the case 
of lymphomas arising in people or mice with inherited 
FAS mutations, most are B-lymphomas, whereas the 
predominant lymphoproliferation is of T cells (Straus et 
al., 2001). Importantly, somatic FAS mutations in non-
Hodgkin’s lymphoma are predominantly in individuals 
with a prior history of autoimmune disease (Gronbaek 
et al., 1998).
Analysis of malignant lymphomas arising following 
autoimmune disease indicates evolution from autore-
active cells. In FasL-deficient mice, the B lymphomas 
express antinuclear BCRs with substitutions typical of 
DNA-reactive B cells in the autoimmune disease (Zhang 
et al., 2004). MALT lymphomas as sequelae of chronic 
gastric infection with Helicobacter pylori often remit upon 
antibiotic treatment, apparently because the lymphoma depends upon growth factors from Helicobacter-reac-
tive CD4 cells (Hussell et al., 1996). One might expect 
the lymphomas would bear BCRs against the microbe, 
but instead they frequently bear VH1-69 BCRs binding 
self-IgG (Bende et al., 2005). Frequent use of V regions 
that confer IgG autoreactivity also occurs in MALT lym-
phomas following Sjogren’s syndrome or thyroid autoim-
munity, and the MALT1 translocation that activates NF-
κB in MALT lymphoma is rarely found in lymphomas with 
antiself IgG BCRs (Bende et al., 2005). As IgG-reactive 
BCRs can capture IgG-chromatin immune complexes to 
activate NF-κB via TLR9 or TLR7 (Marshak-Rothstein, 
2006), MALT lymphomas appear to dysregulate NF-
κB by two alternative pathways: either directly through 
MALT1 translocation or indirectly through expressing a 
BCR that captures autologous TLR ligands.
The VH4-34 heavy chain (formerly VH4-21) is fre-
quently used in BCRs borne by malignant clones in 
cold agglutinin disease, marginal zone lymphomas, and 
Burkitt’s lymphomas (Cappione et al., 2005; Chapman 
et al., 1996; Silberstein et al., 1991). This V region con-
fers strong autoreactivity against autologous N-acetyl-
lactosamine determinants on erythrocyte I/i antigen and 
leukocyte CD45. In normal individuals 5%–10% of the 
naive follicular pool of B cells bear this V region, but they 
are inhibited from accumulating in the germinal center, 
plasma cell, and memory compartments. B cells bearing 
a CLL-derived VH4-34 BCR with antihuman IgG activity 
are normally triggered to die by this antigen (Tighe et 
al., 1995). These tolerance checkpoints break down in 
systemic lupus, where VH4-34+ cells become prevalent 
in germinal centers and secrete anti-leukocyte autoanti-
bodies (Cappione et al., 2005). In a Burkitt’s lymphoma 
derived from VH4-34+ germinal center cells, BCR bind-
ing to self I-I antigen on red cells protected against Fas-
mediated apoptosis (Schattner et al., 2002), illustrat-
ing how relentless stimulation by self-antigens may be 
subverted into a growth stimulus in B cells with multiple 
somatic mutations.
A continuum between autoimmunity and lymphoma 
has also been shown in celiac disease (Cellier et al., 
2000), where ingested wheat triggers gluten-reactive 
CD4 T cells and chronic intestinal inflammation. Inflam-
mation remits when wheat flour is avoided, except in a 
subset of patients where the disease progresses to a 
wheat-independent gut disease called refractory sprue. 
Oligoclonal expansions of intraepithelial T lymphocytes 
accompany this progression, and clonal outgrowths of 
these T cells follow as enteropathy-associated T cell 
lymphoma. The clonal T cell outgrowths display TCR-γ 
rearrangements that may recognize self-antigens.
Rare versus Common Autoimmune Susceptibility 
Genes
As set out in the previous sections, there is a cellular pro-
gression between autoimmunity and lymphoid cancer 
and an overlap in the underlying molecular mechanisms 
that normally prevent uncontrolled growth of lympho-Cell 130, July 13, 2007 ©2007 Elsevier Inc. 31
cytes in both diseases. Views on inherited susceptibility 
to autoimmunity and lymphoma nevertheless diverge. 
A prevalent model of autoimmune disease susceptibil-
ity focuses upon restricted, common polymorphisms: it 
results from a few common susceptibility gene variants 
such as HLA (Todd et al., 1987) and PTPN22 (Gregersen 
et al., 2006) whose high frequency may have been evolu-
tionarily selected in the population because of an advan-
tageous immune response to microbial pathogens. The 
prevailing view of inherited susceptibility to cancer, by 
contrast, is one of multiple rare equivalent risk genes 
(Wright et al., 1999): it results from many different inher-
ited variants in tumor suppressor genes (like BRCA1), 
individually representing relatively rare alleles of no 
particular benefit that are unique to particular families 
or populations but whose cumulative effect is substan-
tial (Fearnhead et al., 2004). Given the large number of 
tolerance checkpoints and genes preventing growth of 
self-reactive lymphocytes and their overlap with tumor 
suppressor mechanisms, it is reasonable to expect that 
inherited susceptibility to autoimmunity will parallel that 
of cancer and involve many equivalent rare alleles.
The germline mutation rate, multiplied over a large 
number of tolerance genes, makes a multiequivalent 
mode of inherited autoimmune susceptibility inevitable 
when compounded by the somatic mutation rate dis-
cussed earlier. By various measures the germline rate is 
one new deleterious mutation per average protein-coding 
gene per 100,000 generations (Haag-Liautard et al., 2007; 
Pritchard, 2001). As there are ?25,000 protein-coding 
genes, this corresponds to a new deleterious mutation 
arising in every fourth child. In a large, outbreeding human 
population of many million, this rate multiplied over sev-
eral hundred critical tolerance genes and several hundred 
recent generations translates into a massive influx of new 
deleterious alleles into our current population. Aside from 
genes on the X chromosome and very specific mutations 
with dominant-negative effects like some FAS alleles, the 
majority of these mutations will have low penetrance in 
heterozygous state, and their frequency will mostly be 
determined by genetic drift and founder effects in par-
ticular families and populations (Pritchard, 2001). It is 
therefore likely that each of us carries multiple deleterious 
rare mutations in critical tolerance genes in heterozygous 
state. However, given the somatic mutation rate of 10−6 
per gene per cell division (Araten et al., 2005) and the fact 
that billions of lymphocytes are produced before adult-
hood, it is inevitable that for each gene where we inherit a 
heterozygous deleterious allele, the remaining functional 
copy will have been lost to somatic mutation in many 
independent lymphocyte clones (Figure 3). As we have 
seen above, self-reactive clones with complete loss of 
genes such as FAS, BIM, CBLB, or CTLA4 have a marked 
growth advantage because they bypass key growth limit 
or override checkpoints. As autoimmunity nevertheless 
has a sporadic onset even when all cells carry germline 
mutations that bypass tolerance mechanisms, it will occur 
even more sporadically and be indiscernible as a distinct 32 Cell 130, July 13, 2007 ©2007 Elsevier Inc.inherited disorder when a heterozygous defect is inher-
ited and the second hit occurs stochastically in individual 
lymphocytes or hematopoietic progenitors. Like cancer, 
many equivalent rare inherited variants may eventually 
manifest in common autoimmune disease endpoints that 
appear indistinguishable by our current diagnostic tools.
Practical Implications
There are several practical implications of this multistep 
view of autoimmune pathogenesis. First, sporadic auto-
immune diseases that appear equivalent may be distin-
guished by testing known tolerance genes for heterozy-
gous deleterious mutations in the germline. Inheritance 
of a heterozygous defect may predict the pathway by 
which autoimmune clones have bypassed normal check-
points somatically, whereas detecting somatic second 
hits in self-reactive clones would be more difficult. Iden-
tification of germline or somatic mutations would pro-
vide a way to stratify the likelihood of response to path-
way-specific therapeutics as is the case for treatment 
of chronic myeloid leukemia with Gleevec. Second, the 
multistep hypothesis for autoimmunity suggests cancer-
related strategies aimed at eliminating the rogue clones 
of autoimmune cells. If the autoimmune driver clones are 
partially dysregulated by inherited and somatic muta-
tions, then, like cancer cells, they may be hypersensi-
tive to particular drugs compared to their normal coun-
terparts and thus selectively eliminated. For example, 
the efficacy of cancer therapeutics such as Rituximab 
against some autoimmune diseases and their capac-
ity to suppress autoimmunity to a greater degree than 
immunity to infection may stem from somatic mutations 
that sensitize the autoimmune clones.
Note
Since submitting this manuscript, my colleague Dr. Stephen Daley 
has drawn my attention to F.M. Burnet’s extraordinary 1972 book 
(Burnet, 1972). This monograph assembled the limited information 
about lymphocytes at that time to arrive at the same hypothesis de-
veloped here—that the stochastic onset of autoimmunity reflects “a 
conditioned malignancy” caused by emergence of “forbidden clones” 
through a combination of germline and somatic mutations that disrupt 
the normal mechanisms for eliminating or inactivating self-reactive 
lymphocytes.
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